Diary - News
All news Poxel Announces Positive Top Line Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes
• Imeglimin Phase 2b trial in 299 Japanese patients achieved statistical significance for the primary and key secondary endpoints • Les rés
• Imeglimin Phase 3 program in Japan is anticipated to initiate in the fourth quarter of 2017
• The Japanese diabetes market is fast-growing and anticipated to reach approximately $6B by 2020
Lyon, France, May 4, 2017 – POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat metabolic diseases, including type 2 diabetes, announced today positive top line Phase 2b data results for Imeglimin for the treatment of type 2 diabetes in Japan.
